Becton, Dickinson and Company (NYSE:BDX - Get Free Report) EVP Michael David Garrison sold 2,838 shares of Becton, Dickinson and Company stock in a transaction dated Thursday, December 19th. The stock was sold at an average price of $223.33, for a total transaction of $633,810.54. Following the transaction, the executive vice president now directly owns 6,141 shares of the company's stock, valued at approximately $1,371,469.53. This represents a 31.61 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Becton, Dickinson and Company Stock Performance
Shares of Becton, Dickinson and Company stock opened at $227.68 on Friday. Becton, Dickinson and Company has a 12 month low of $218.75 and a 12 month high of $249.89. The stock's fifty day moving average price is $229.88 and its 200-day moving average price is $233.19. The firm has a market cap of $65.83 billion, a P/E ratio of 38.33, a P/E/G ratio of 1.64 and a beta of 0.41. The company has a current ratio of 1.17, a quick ratio of 0.74 and a debt-to-equity ratio of 0.69.
WARNING: “Buffett Indicator” flashing for first time in 50 years
From Behind the Markets | Ad
Warren Buffett has sold a staggering $97 billion worth of stocks this year...
But why?
Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash.
His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.
Take these 4 steps today to protect your retirement NOW
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 EPS for the quarter, beating analysts' consensus estimates of $3.77 by $0.04. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. The business had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. During the same quarter last year, the firm posted $3.42 EPS. The company's revenue for the quarter was up 6.9% on a year-over-year basis. On average, equities research analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.
Becton, Dickinson and Company Increases Dividend
The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 31st. Shareholders of record on Monday, December 9th will be given a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a yield of 1.83%. The ex-dividend date is Monday, December 9th. This is a boost from Becton, Dickinson and Company's previous quarterly dividend of $0.95. Becton, Dickinson and Company's dividend payout ratio (DPR) is 70.03%.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently made changes to their positions in BDX. WR Wealth Planners LLC lifted its position in Becton, Dickinson and Company by 1.4% during the second quarter. WR Wealth Planners LLC now owns 2,978 shares of the medical instruments supplier's stock valued at $696,000 after acquiring an additional 42 shares during the last quarter. Clear Creek Financial Management LLC lifted its holdings in shares of Becton, Dickinson and Company by 5.1% during the 2nd quarter. Clear Creek Financial Management LLC now owns 900 shares of the medical instruments supplier's stock valued at $210,000 after purchasing an additional 44 shares during the last quarter. Sound Income Strategies LLC grew its stake in Becton, Dickinson and Company by 35.8% during the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier's stock worth $40,000 after buying an additional 44 shares during the last quarter. Central Pacific Bank Trust Division raised its stake in Becton, Dickinson and Company by 22.5% in the third quarter. Central Pacific Bank Trust Division now owns 245 shares of the medical instruments supplier's stock valued at $59,000 after buying an additional 45 shares during the last quarter. Finally, Tompkins Financial Corp raised its stake in Becton, Dickinson and Company by 44.2% in the third quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier's stock valued at $36,000 after buying an additional 46 shares during the last quarter. 86.97% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
A number of research firms have recently commented on BDX. StockNews.com cut Becton, Dickinson and Company from a "buy" rating to a "hold" rating in a research note on Wednesday. Citigroup upgraded Becton, Dickinson and Company from a "neutral" rating to a "buy" rating and lifted their target price for the stock from $255.00 to $275.00 in a research report on Tuesday, October 1st. Finally, Evercore ISI upped their price target on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an "outperform" rating in a report on Tuesday, October 1st. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, Becton, Dickinson and Company has an average rating of "Moderate Buy" and a consensus target price of $283.50.
Check Out Our Latest Stock Report on BDX
About Becton, Dickinson and Company
(
Get Free Report)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
